The study found that states with medical cannabis legalization experienced a 19.7 percent decrease in Medicare Part D opioid prescriptions written by orthopedic surgeons compared to states without legalization. States with active storefront dispensaries experienced a 13.1 percent decrease in those prescriptions.
“Although our study does not support a direct causal relationship, these population-level findings show that legalization of medical cannabis and patient access to dispensaries may be associated with reductions in opioid prescribing by orthopaedic surgeons,” the researchers wrote in The Journal of the American Academy of Orthopaedic Surgeons.
In the study’s conclusion, the authors argue that their findings highlight the importance of offering patients alternatives for pain management.
More articles on opioids:
‘This is how it needs to be’: Physicians call for permanent changes to addiction medicine
5 states with the most, fewest overdose deaths
Pharmacy chains helped fuel opioid crisis, complaint alleges
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
